Lupin Limited has achieved a remarkable milestone by securing the No. 1 position globally in the pharmaceutical sector and leading all sectors in India in the S&P Global Corporate Sustainability Assessment 2025. The company announced this achievement on February 26, 2026, highlighting its exceptional performance in environmental, social, and governance (ESG) criteria.

Outstanding Performance in Global ESG Assessment

Lupin attained an impressive score of 91 out of 100 in the comprehensive assessment, establishing itself among the top 1% of companies worldwide. This achievement places the company ahead of both Indian and international peers across all evaluated sectors.

Third Consecutive Yearbook Inclusion

The S&P Global Corporate Sustainability Assessment represents one of the world's most comprehensive ESG benchmarks, evaluating companies on industry-specific economic, environmental, and social criteria. Lupin has earned inclusion in the Sustainability Yearbook 2026 for the third consecutive year, demonstrating consistent excellence in sustainability practices.

The selection criteria for Yearbook inclusion are highly stringent:

• Companies must rank in the top 15% of their industry
• Scores must be within 30% of the industry's top performer
• Of more than 9,200 companies assessed across 59 industries, only 848 earned inclusion

Leadership Commitment to Sustainability

Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, emphasized the significance of this recognition. He stated that this achievement places Lupin among the topmost global sustainability leaders and reinforces the company's long-term commitment to embedding ESG principles into business strategy.

Strategic ESG Integration

Lupin's recognition reflects its sustained focus on several key areas:

• Responsible business practices across global operations
• Strong governance frameworks
• Environmental stewardship initiatives
• Positive social impact programs
• ESG integration across the entire value chain

The company's performance demonstrates its commitment to creating positive outcomes for patients, communities, and stakeholders worldwide while maintaining leadership in pharmaceutical innovation and manufacturing excellence.

Global Pharmaceutical Leadership

As a global pharmaceutical leader headquartered in Mumbai, India, Lupin distributes products in over 100 markets. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals. This extensive infrastructure enables Lupin to maintain its position as a trusted provider of pharmaceutical products while adhering to the highest sustainability standards.

Lupin Limited has informed stock exchanges about GST Department inspection and search proceedings initiated at its registered office on February 25, 2026. The pharmaceutical company made the disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

GST Department Action Details

The inspection was conducted by the Assistant Commissioner of State Tax, Maharashtra under Section 67 of Maharashtra Goods & Service Tax Act, 2017. The proceedings commenced at 11.50 a.m. (IST) on February 25, 2026, at the company's registered office located at Kalpaturu Inspire, Off W. E. Highway, Santacruz (East), Mumbai.

Company's Response and Cooperation

Lupin has confirmed that it is extending full cooperation with the GST officials and providing all necessary information and documents as requested. The company secretary and compliance officer, Amit Kumar Gupta, signed the disclosure document digitally on February 25, 2026. The company is actively cooperating with the ongoing inspection proceedings at its Maharashtra office.

Impact Assessment

According to the company's disclosure, the initiation of this inspection and search does not have any impact on Lupin's financials, operations or other activities. The company has characterized this as a routine inspection seeking documentation related to GST compliance and input tax credit claims.

Regulatory Compliance

The disclosure was made to both the National Stock Exchange of India Limited and BSE Limited as required under SEBI Listing Regulations. The company provided detailed information in the prescribed format, including the nature of the action, authority involved, and potential impact on business operations.